Isomorphic Labs company profile: valuation, funding & revenue

This Isomorphic Labs company profile covers the company's valuation, revenue, funding rounds, investors and history. Isomorphic Labs works in artificial intelligence, with a focus on AI drug discovery. It was founded in 2021 and is headquartered in London, United Kingdom. Every figure links to a public source, and anything the company hasn't disclosed is marked as such.

Revenue

Funding history

Isomorphic Labs timeline

Key dates from the sources on this page, oldest first. Metric snapshots are listed after the funding events.

• 2021 — Isomorphic Labs is founded in London by Demis Hassabis (CEO).
• Mar 2025 — Series A: US$600M. Investors: Thrive Capital (lead); GV, Alphabet.
• 2026 — Series B: US$2.1B. Investors: Alphabet, Alphabet venture funds (including GV) and external backers.
• October 2026 — Reported talks: Early talks to raise at a valuation of at least US$40 billion, possibly up to US$50 billion.
• 2026 — Pharma partnerships: Deals with Eli Lilly and Novartis worth nearly US$3 billion combined (2024); collaboration with Johnson & Johnson (2026).

Investors

Overview

Isomorphic Labs uses artificial intelligence to discover new medicines. It was spun out of Google DeepMind to build on AlphaFold, the AI system that predicts the 3D structure of proteins, a breakthrough that won its creators a share of the 2024 Nobel Prize in Chemistry. Isomorphic's goal is to use AI to model biology and chemistry so accurately that drug discovery becomes faster, cheaper and more successful, and eventually, as its founder puts it, to solve disease.

Demis Hassabis, co-founder and CEO of Google DeepMind and a co-recipient of that Nobel Prize, founded Isomorphic Labs in London in 2021 and is also its CEO. The company is a subsidiary of Alphabet, Google's parent, but has raised outside capital too. It has offices in London and Lausanne, Switzerland, and has built a team combining AI researchers with medicinal chemists and biologists.

What Isomorphic does

Developing a new drug typically takes more than a decade and costs billions of dollars, and most candidates fail in clinical trials. A major reason is that it's hard to predict how a potential drug molecule will interact with its target in the body, and with everything else. Isomorphic's platform, called IsoDDE, models these interactions: how small molecules and antibodies bind to proteins, where binding pockets exist, and how changes to a molecule affect its behaviour. The company says IsoDDE significantly outperforms AlphaFold on several of these tasks. With better predictions, chemists can design and test fewer, better candidates.

Isomorphic also worked with Google DeepMind on AlphaFold 3, released in 2024, which extended structure prediction from proteins to interactions with DNA, RNA and small molecules.

Partnerships

In 2024 Isomorphic signed research collaborations with Eli Lilly and Novartis, worth nearly US$3 billion combined in potential milestone payments and royalties, focused on small-molecule drugs. In 2026 it launched a collaboration with Johnson & Johnson. It is also developing its own internal drug programmes, initially in areas such as oncology and immunology. Hassabis has said he hopes the first AI-designed drugs from Isomorphic will enter clinical trials soon.

How it makes money

Isomorphic earns upfront payments from pharmaceutical partners, with the potential for much larger milestone payments as drug candidates advance through development and royalties on sales if drugs are approved. Owning its internal programmes could eventually be more valuable, since it would capture more of the economics, but those take years and significant capital. It doesn't publish revenue.

Funding

• March 2025, Series A: US$600 million, its first external round, led by Thrive Capital with GV and Alphabet.
• 2026, Series B: US$2.1 billion with Alphabet, Alphabet's venture funds and external backers. Reports differ on whether it was announced in March or May.
• October 2026: Bloomberg reported early talks to raise at a valuation of at least US$40 billion, possibly up to US$50 billion. The talks were early and the company hadn't confirmed a valuation.

Because no valuation has been officially disclosed for its rounds, we show valuation as not disclosed and record the reported talks separately.

Competition

Isomorphic competes with AI drug discovery companies such as Recursion, Insilico Medicine, Xaira Therapeutics and Generate Biomedicines, with pharmaceutical companies' in-house AI teams, and with Nvidia-backed platforms. Its advantages are the AlphaFold heritage, access to Alphabet's computing resources and talent, and the scientific credibility of its leadership.

Isomorphic Labs at a glance

Isomorphic Labs is a London AI drug discovery company founded in 2021 by Demis Hassabis as an Alphabet subsidiary. It raised US$600 million led by Thrive Capital in March 2025 and US$2.1 billion in 2026, and has partnerships with Eli Lilly, Novartis and Johnson & Johnson. Reports in October 2026 described talks at a valuation of US$40 billion or more.

Why AI could change drug discovery

Most of drug discovery's cost comes from failure: candidates that look promising in the lab but fail in animals or humans. If AI can predict which molecules will bind well, be safe and reach the right part of the body, companies could avoid many of those failures and reach good candidates faster. The scepticism comes from history: earlier waves of computational drug design over-promised. The real test is clinical: whether AI-designed drugs succeed in trials at higher rates than conventional ones. Only a few have reached late-stage trials so far.

Valuation before clinical proof

A US$40 billion valuation would be extraordinary for a company without approved drugs or late-stage trials. Investors are pricing in the potential for a platform that improves drug discovery across many diseases and partners. Our guide to pre-revenue valuation methods discusses how investors assess companies whose value depends on future milestones.

Questions for pharma partners

• How have predictions compared with experimental results on our targets?
• Who owns the intellectual property for molecules designed together?
• How are milestones and royalties structured?

The Alphabet relationship

Isomorphic is unusual among AI startups because it is a subsidiary of one of the world's largest technology companies, yet it has also raised billions from outside investors. The arrangement gives it access to Alphabet's computing power, research culture and links with Google DeepMind, while outside capital and a separate identity help it recruit and give employees a stake in its success. For investors, the structure raises questions about how value is shared with Alphabet and how decisions are made, but it also provides unusual financial stability for a company with long development timelines. Few independent biotech companies anywhere have backing on anything like this scale.

Upcoming milestones

Watch for the first clinical trials of Isomorphic-designed drugs, new pharma partnerships, a confirmed funding round and further model releases.

Reader takeaways

Pharma executives can access cutting-edge AI through partnerships. Biotech founders should note how AI is reshaping investor expectations. Investors should remember that clinical results, not model benchmarks, will ultimately determine value.

Latest developments (October 2026)

Isomorphic Labs raised US$2.1 billion in May 2026 in a round led by Thrive Capital at an undisclosed valuation, according to Reuters as reported by ARY News. In October 2026 Bloomberg reported early talks to raise new funds at a valuation of at least US$40 billion and possibly up to US$50 billion, according to Bloomberg Government; that round had not closed. See our AI drug discovery guide.

Sources

Every figure on this page comes from the public sources below. Where sources disagreed, we used the company's own announcement or a primary news report. Private-company data changes; check the date beside each figure.

1. SiliconANGLE
2. Yahoo Finance